SCHEMBL237870

SCHEMBL237870

COc1ccc(-c2cc3ncc4cc(-c5ccccc5)c(=O)[nH]c4n3n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.60
RAB9A P51151 7/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
ALDH1A1 P00352 6/20 0.60
STAT1 P42224 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
AURKA O14965 1/20 0.52
INSR P06213 1/20 0.49
KDR P35968 1/20 0.49
PLK1 P53350 1/20 0.49
MAPT P10636 4/20 0.47
ADORA3 P0DMS8 1/20 0.46
KDM4E B2RXH2 6/20 0.46
HPGD P15428 3/20 0.43
PKM P14618 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
ACACA Q13085 1/20 0.43
DYRK1A Q13627 1/20 0.43
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755211 0.88 NPC1 (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL238993 0.86 HPGD (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL238085 0.86 KDM4E (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL240253 0.85 NPC1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL237827 0.81 NPC1 (0.44) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL237769 0.81 AURKA (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1AURKA
SCHEMBL239224 0.81 NPC1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL237826 0.79 MET (0.38) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1
SCHEMBL238752 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EPKMRXFP1
SCHEMBL236540 0.78 AURKA (0.38) NPC1RAB9ASMN1; SMN2ALDH1A1STAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.